AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q2 FY24 results · Jul–Sep 2023
AstraZeneca Pharma India reported revenue from operations of ₹311.07 crore (up 31.7% from Q2 FY23) and net profit of ₹52.37 crore (up 60.8% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a standalone basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 311.07 | 236.13 | +31.7% | 295.47 | +5.3% |
| Other income | 8.37 | 6.79 | +23.2% | 8.10 | +3.3% |
| Total income | 319.44 | 242.92 | +31.5% | 303.57 | +5.2% |
| Profit before tax | 73.38 | 44.07 | +66.5% | 71.40 | +2.8% |
| Net profit for the period | 52.37 | 32.56 | +60.8% | 53.86 | −2.8% |
| EPS, basic (₹) | 20.95 | 13.03 | +60.8% | 21.54 | −2.8% |
| Net margin (%) | 16.8 | 13.8 | 18.2 |
Standalone
- Filed with BSE
- 13 Nov 2023, 14:47 IST
- Board meeting
- 09 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE